For general education only. This information does not diagnose a condition or replace medical advice. Your provider will determine which evaluation or treatment is appropriate for you.
How to read this table
This table compares categories of options. It does not rank them, declare a winner, or suggest that any option is right for you. Your provider determines suitability after reviewing your health history, current medicines, labs, and goals. Nothing here replaces that evaluation.
These three tablets are not the same class of medicine. One acts on insulin and glucose, the others on appetite pathways. The labeling question is usually the most important one to resolve first.
Approval, off label use, and compounding
FDA approval applies to a specific product, formulation, indication, and population. Off label use means an approved medicine is prescribed outside its approved labeling. A compounded preparation is not FDA approved and has not undergone the same premarket review for safety, effectiveness, and quality.
A tablet form of an ingredient is a different product from an injectable form of the same ingredient, and it may not carry the same approved uses. An ingredient name alone does not establish approval. Ask for the exact product name, formulation, and current labeling of the medicine offered to you, and whether that use is approved, off label, or compounded.
What a useful conversation covers
Ask what the medicine is expected to change for you, how quickly that should become visible, and what your provider will do if it does not. Metformin and appetite pathway medicines answer different questions.
Ask about timing with food, digestive effects, and any labs your provider wants before or during use.
Side by side
Considerations worth bringing to your provider. This is not a ranking, and it does not mean any option is right for you.
Semaglutide tablet
Product details- What it is
- An oral form of a medicine that acts on the GLP-1 pathway involved in appetite and blood sugar regulation.
- How it is used
- Taken once a day, typically on an empty stomach as your provider directs.
- Approval and labeling
- Oral semaglutide products carry their own labeling, which is not the same as the injectable products. Ask which product is offered and what it is approved for.
- What the evidence supports
- Evidence for appetite and weight effects applies to specific products and populations. Ask what human evidence supports the exact product offered.
- Common considerations
- Nausea, vomiting, diarrhea, or constipation may occur. Timing with food matters for absorption.
- Often not appropriate when
- There is a personal or family history of medullary thyroid carcinoma or MEN 2, or during pregnancy.
- Cost and access
- Pricing is shared after your evaluation. Ask what your plan includes, such as consultations, medication, labs, and follow up, and what happens if your plan changes.
Tirzepatide tablet
Product details- What it is
- An oral form of a medicine that acts on the GIP and GLP-1 pathways involved in appetite and metabolism.
- How it is used
- Taken once a day as your provider directs.
- Approval and labeling
- An oral tirzepatide product should not be assumed to share the labeling of an injectable. Ask for the exact product and whether it is approved, off label, or compounded.
- What the evidence supports
- Ask what human evidence supports the exact formulation offered, and how it was studied.
- Common considerations
- Nausea, vomiting, diarrhea, or constipation may occur.
- Often not appropriate when
- There is a personal or family history of medullary thyroid carcinoma or MEN 2, or during pregnancy.
- Cost and access
- Pricing is shared after your evaluation. Ask what your plan includes, such as consultations, medication, labs, and follow up, and what happens if your plan changes.
Metformin
Product details- What it is
- A long established medicine that reduces glucose made by the liver and may improve how the body responds to insulin.
- How it is used
- Taken with meals, usually daily as your provider directs.
- Approval and labeling
- Approved for type 2 diabetes. Use for weight management may be off label and needs its own discussion of evidence and risks.
- What the evidence supports
- Strong evidence for blood sugar control. Evidence for meaningful weight change in women without diabetes is more limited.
- Common considerations
- Digestive upset is common early and often eases. Rarely, lactic acidosis occurs, especially with kidney problems or heavy alcohol use.
- Often not appropriate when
- There is significant kidney disease or other contraindications your provider identifies.
- Cost and access
- Pricing is shared after your evaluation. Ask what your plan includes, such as consultations, medication, labs, and follow up, and what happens if your plan changes.
Questions to bring
- Is this a tablet version of an injectable medicine, and does the labeling differ?
- Is the use you are proposing approved, off label, or compounded?
- What human evidence supports this exact product for my goal?
- How will we know it is helping, and by when?